Cube Pharmaceuticals announced that Hefei Norit Pharmaceutical Co., Ltd., a holding subsidiary of the company, recently received the “Drug Registration Certificate” for gatifloxacin eye drops approved and issued by the State Drug Administration. The drug is registered and classified as a chemical class 3, with a specification of 0.3%. The drug approval number is Sinopharm Standard H20266445. It is valid until November 2, 2031, and the marketing license holder is Norit. Gatifloxacin eye drops are mainly used for acute bacterial conjunctivitis caused by sensitive bacteria. As of the announcement date, in addition to the company, 10 other domestic companies had pharmaceutical approvals for this product.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.